HSBC analyst Rajesh Kumar raised the firm’s price target on Merck (MRK) to $120 from $100 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Merck price target raised to $122 from $104 at Guggenheim
- Merck & Co. Closes $7 Billion Notes Offering
- Halozyme wins preliminary injunction against Merck’s Keytruda SC in Germany
- Merck Animal Health announces conditional FDA approval of Exzolt Cattle-CA1